Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXRG001 in Radiation-Induced Xerostomia and Hyposalivation
NCT06714253Phase 2Recruiting
- Sponsor
- RiboX Therapeutics
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of RXRG001 in radiation-induced xerostomia, hyposalivation, sponsored by RiboX Therapeutics. Started Mar 2025; status: recruiting.
02
Drugs
RXRG001
03
Conditions
radiation-induced xerostomiahyposalivation
Beyond the preview
Go deeper on NCT06714253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714253.